This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Hello, I think we will get started here and thanks everyone for joining us. Dave Friedman, one of the biotech analyst here and in terms of disclosures, you can find personnel and research at Morgan Stanley disclosures on morganstanley.com/researchdisclosures. So more exciting things, I've got Craig Wheeler here, CEO and President of Momenta Pharmaceuticals and we're very happy to have you here and the team and maybe if we can start if you can just give, you know, one or two minute overview of the company and you guys have a very unique approach to the drug development world and so maybe a quick intro and then we’ll just jump right in.
Sure. I would be happy to. And for those of you that follow the company long time, you know, it's really a challenge to give a short intro on the complexity of our company in two minutes, but I'll give you just a quick profile of who Momenta is and we're a company that was found and based on really unraveling complexity. I think that’s a simplest way to put it where we look at complex problems like biologics, like heparins and try to understand in much more detail the structure, the manufacturing and the biology of this.